The vesicular monoamine transporter is not regulated by dopaminergic drug treatments.
The vesicular monoamine transporter is not regulated by dopaminergic drug treatments.
复制标题
囊泡单胺转运蛋白不受多巴胺能药物治疗的调节。
DOI：
10.1016/0014-2999(95)00594-3
复制
发表时间：
1995
影响因子：
5
通讯作者：
Frey,K
中科院分区：
文献类型：
--
作者：
VanderBorght,T;Kilbourn,M;Desmond,T;Kuhl,D;Frey,K
神经元突触囊泡单胺转运体（囊泡单胺转运体2型; VMAT 2）的数量最近已被提出作为单胺突触前终末密度的指标。本研究探讨了囊泡单胺转运体的可能调控。大鼠用已知影响多巴胺能神经传递的药物治疗2周，包括那些常用于治疗帕金森病的药物。使用[3 H]甲氧基丁苯那嗪、[3 H]雷氯必利和[3 H]WIN 35，428（[3 H]2β-甲氧羰基-3 β-（4-氟苯基）托烷）进行放射自显影试验，分别测量囊泡单胺转运蛋白、多巴胺D2受体和突触质膜多巴胺再摄取位点结合。没有一种药物治疗显著改变囊泡单胺转运蛋白结合水平。与此相反，多巴胺D2受体和多巴胺再摄取位点都被一些治疗方案改变。这些数据扩展了初步结果，表明囊泡单胺转运蛋白不容易调节，并确认多巴胺D2受体和多巴胺再摄取位点的可塑性。纹状体囊泡单胺转运体密度的措施，因此，提供客观的估计单胺能神经支配的神经退行性疾病，使用对症治疗的影响。
The number of neuronal synaptic vesicular monoamine transporters (vesicular monoamine transporter type 2; VMAT2) has been recently proposed as an index of monoamine presynaptic terminal density. The present study investigated the possible regulation of the vesicular monoamine transporter. Rats were treated for 2 weeks with drugs known to influence dopaminergic neurotransmission, including those commonly used in the treatment of Parkinson's disease. Autoradiographic assays were performed using [3H]methoxytetrabenazine, [3H]raclopride, and [3H]WIN 35,428 ([3H]2β-carbomethoxy-3β-(4-fluorophenyl)tropane) to measure vesicular monoamine transporter, dopamine D2receptor and synaptic plasma membrane dopamine re-uptake site bindings, respectively. None of the drug treatments significantly modified levels of vesicular monoamine transporter binding. In contrast, both dopamine D2receptors and dopamine re-uptake sites were altered by some of the treatment regimens. These data extend preliminary results that suggest the vesicular monoamine transporter is not easily regulated and confirm the plasticity of dopamine D2receptors and the dopamine re-uptake site. Measures of striatal vesicular monoamine transporter density may, thus, provide objective estimates of monoaminergic innervation in neurodegenerative diseases, unaffected by the use of symptomatic therapies.